Hard to Copy Is Easy to Value

L’Oréal doesn’t lack money or labs. What it lacks is seven years of India-specific consumer trust, D2C muscle, and proprietary formulation depth. That’s why it’s reportedly paying ₹4,000 crore for Innovist. HUL doesn’t lack brand-building capability. What it couldn’t build fast enough was Minimalist’s ingredient-loyal consumer community so it paid ₹2,955 crore for it instead. In both cases, the premium wasn’t for the brand. It was for the irreplaceable asset underneath it.Meanwhile, India’s regional pharma companies have built nothing irreplaceable. 8000+ MSME players buy the same molecules from the same CDMOs, push them through MR networks to the same doctors, and call the result a branded business. The patient, the chronic-disease sufferer who will take the same tablet for twenty years, has no relationship with the company whatsoever. That’s not a brand. That’s a distribution arrangement wearing a logo.On this episode, we talk about how the consolidation cycle in Indian pharma has begun. Schedule M compliance deadlines are already straining the weakest players. Large groups are acquiring for capability, not revenue. Distressed exits at book value are coming for those who built nothing proprietary. Premium acquisitions will go to the few who built what money alone cannot replicate like a formulation that’s patented, brands with solid patient relationships, a distribution asset that took a decade to build. Promoters need to think about what they own/built that a well-capitalised competitor couldn’t rebuild in eighteen months? If the answer isn’t clear, you already have your answer.Listen in for a more detailed analysis. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com